Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Vaginal Estradiol vs Oral Beta-3 Agonist for Treatment of Overactive Bladder Syndrome: A Single-Therapy, Double-Blind, Randomized Controlled Trial

NCT05221021 is registered in ClinicalTrials.gov with Walter Reed National Military Medical Center as lead sponsor.

NCT NCT05221021
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05221021 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Vaginal Estradiol vs Oral Beta-3 Agonist for Treatment of Overactive Bladder Syndrome: A Single-Therapy, Double-Blind, Randomized Controlled Trial
Lead sponsor
Walter Reed National Military Medical Center
Phase
Phase 4
Overall status
Recruiting
Start date
October 1, 2022
Completion date
January 30, 2027
Enrollment
152 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

overactive bladder syndrome